menu search

CYAD / Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 – 26, 2022. Read More
Posted: May 17 2022, 16:05
Author Name: GlobeNewsWire
Views: 103144

CYAD News  

Celyad Oncology to announce full year 2022 financial results and host conference call

By GlobeNewsWire
March 17, 2023

Celyad Oncology to announce full year 2022 financial results and host conference call

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company more_horizontal

Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 5, 2022

Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript

Celyad Oncology SA (NASDAQ:CYAD ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sara Zelkovic - Director, Communicat more_horizontal

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

By GlobeNewsWire
July 28, 2022

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo more_horizontal

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

By Business Wire
July 28, 2022

Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) more_horizontal

Celyad: Probably Still Top-Notch In Oncology

By Seeking Alpha
July 19, 2022

Celyad: Probably Still Top-Notch In Oncology

Celyad is a seemingly neglected immuno-oncology-focused nano-cap, liked by analysts and experts abound, but somehow overlooked by the market. Four mon more_horizontal

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

By GlobeNewsWire
May 17, 2022

Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biote more_horizontal

Celyad Oncology SA (CYAD) CEO Filippo Petti on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 25, 2022

Celyad Oncology SA (CYAD) CEO Filippo Petti on Q4 2021 Results - Earnings Call Transcript

Celyad Oncology SA (CYAD) CEO Filippo Petti on Q4 2021 Results - Earnings Call Transcript more_horizontal

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

By Business Wire
March 17, 2022

Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) more_horizontal


Search within

Pages Search Results: